Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GANAB | Q14697 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205442 | 1.00 | CHRNA7 (0.36) | CHRNA7MAN2B1SLC18A3CHRM2CHRM1 | |
| SCHEMBL4649804 | 1.00 | CHRNA7 (0.36) | CHRNA7MAN2B1SLC18A3CHRM2CHRM1 | |
| SCHEMBL412997 | 1.00 | CHRNA7 (0.36) | CHRNA7MAN2B1SLC18A3CHRM2CHRM1 | |
| SCHEMBL3965421 | 1.00 | CHRNA7 (0.36) | CHRNA7MAN2B1SLC18A3CHRM2CHRM1 | |
| SCHEMBL15451780 | 0.91 | CHRNA7 (0.41) | CHRNA7MAN2B1SLC18A3CHRM2CHRM1 | |
| SCHEMBL11230330 | 0.87 | — | — | |
| SCHEMBL8758466 | 0.83 | — | — | |
| SCHEMBL4528256 | 0.83 | — | — | |
| SCHEMBL8758623 | 0.83 | — | — | |
| SCHEMBL13412394 | 0.76 | SLC18A3 (0.38) | CHRNA7MAN2B1SLC18A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | claimed |
| EP-1761533-B8 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | claimed |
| EP-2336129-A1 | 1-aza-bicyclo[3.3.1]nonanes | Novartis AG (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG | 2011-02-10 | — | — | US | claimed |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | claimed |
| EP-1761533-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | Novartis AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123732-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | claimed |
| US-9475811-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-8933090-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-20140113908-A1 | [(1H-INDOL-5-YL) - HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| US-20070197584-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| WO-2007068476-A1 | [ (1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS. | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| EP-1761533-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123732-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197584-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | CHRNA7 3447/4885MAN2B1 2313/4885SLC18A3 889/4885 |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | CBR3, CBR1, HCAR3 | CHRNA7 119/4885MAN2B1 1957/4885SLC18A3 2385/4885 |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, HRH4 | CHRNA7 208/4885MAN2B1 1910/4885SLC18A3 2046/4885 |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, ADCY3 | CHRNA7 228/4885MAN2B1 2217/4885SLC18A3 2189/4885 |
| US-20140113908-A1 | [(1H-INDOL-5-YL) - HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS | CHRNA5, CHRNA7, CHRNA6 | CHRNA7 2/4885MAN2B1 3013/4885SLC18A3 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.